{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["30(5)"],"submitter":["Hao W"],"pubmed_abstract":["This case report presents the first occurrence of <i>Pneumocystis jirovecii</i> pneumonia in a patient with breast cancer during CDK4/6 inhibitor therapy. Abemaciclib serves as a first-line therapeutic option for hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer. However, there are no documented cases in the literature linking abemaciclib to <i>Pneumocystis jirovecii</i> pneumonia. Notably, although rare, abemaciclib-induced severe lymphopenia may predispose patients to potentially life-threatening opportunistic infections. Optimal patient management requires multidisciplinary collaboration and strict compliance with American Society of Clinical Oncology/European Society for Medical Oncology guidelines to optimize the balance between therape"],"journal":["Oncology letters"],"pagination":["505"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12434459"],"repository":["biostudies-literature"],"pubmed_title":["&lt;i&gt;Pneumocystis jirovecii&lt;/i&gt; pneumonia in a patient with HR&lt;sup&gt;+&lt;/sup&gt;/HER2&lt;sup&gt;-&lt;/sup&gt; advanced breast cancer following abemaciclib combined with endocrine therapy: A case report."],"pmcid":["PMC12434459"],"pubmed_authors":["Bao J","Sun C","Wu C","Hao W","Qin Y","Liu S"],"additional_accession":[]},"is_claimable":false,"name":"&lt;i&gt;Pneumocystis jirovecii&lt;/i&gt; pneumonia in a patient with HR&lt;sup&gt;+&lt;/sup&gt;/HER2&lt;sup&gt;-&lt;/sup&gt; advanced breast cancer following abemaciclib combined with endocrine therapy: A case report.","description":"This case report presents the first occurrence of <i>Pneumocystis jirovecii</i> pneumonia in a patient with breast cancer during CDK4/6 inhibitor therapy. Abemaciclib serves as a first-line therapeutic option for hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer. However, there are no documented cases in the literature linking abemaciclib to <i>Pneumocystis jirovecii</i> pneumonia. Notably, although rare, abemaciclib-induced severe lymphopenia may predispose patients to potentially life-threatening opportunistic infections. Optimal patient management requires multidisciplinary collaboration and strict compliance with American Society of Clinical Oncology/European Society for Medical Oncology guidelines to optimize the balance between therape","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Nov","modification":"2026-04-08T19:52:33.955Z","creation":"2026-04-08T14:35:41.843Z"},"accession":"S-EPMC12434459","cross_references":{"pubmed":["40959712"],"doi":["10.3892/ol.2025.15251"]}}